Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AR | P10275 | 1/20 | 0.33 |
| ▸ | TLR9 | Q9NR96 | 2/20 | 0.32 |
| ▸ | TLR8 | Q9NR97 | 2/20 | 0.32 |
| ▸ | TLR7 | Q9NYK1 | 2/20 | 0.32 |
| ▸ | AVPR2 | P30518 | 1/20 | 0.31 |
| ▸ | AVPR1A | P37288 | 1/20 | 0.31 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.30 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4149567 | 0.86 | AR (0.50) | ARAVPR2AVPR1A | |
| SCHEMBL4149574 | 0.86 | AR (0.50) | ARAVPR2AVPR1A | |
| SCHEMBL4142968 | 0.85 | PDE3B (0.37) | ARTLR9TLR8TLR7PDE3B | |
| SCHEMBL4134415 | 0.73 | AR (0.50) | ARAVPR2AVPR1A | |
| SCHEMBL4148811 | 0.73 | AR (0.50) | ARAVPR2AVPR1A | |
| SCHEMBL4134411 | 0.73 | AR (0.50) | ARAVPR2AVPR1A | |
| SCHEMBL4139051 | 0.71 | AR (0.65) | AR | |
| SCHEMBL9885147 | 0.70 | AR (0.53) | ARAVPR2AVPR1A | |
| SCHEMBL4134427 | 0.70 | AR (0.53) | ARAVPR2AVPR1A | |
| SCHEMBL4134431 | 0.70 | AR (0.53) | ARAVPR2AVPR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8193357-B2 | Androgen receptor modulator compounds | LIGAND PHARMACEUTICALS INCORPORATED (US) | 2012-06-05 | — | — | US | disclosed |
| US-20090264455-A9 | Androgen Receptor Modulator Compounds and Methods | LIGAND PHARMACEUTICALS INCORPORATED (US) | 2009-10-22 | — | — | US | disclosed |
| US-20090030027-A1 | Androgen Receptor Modulator Compounds and Methods | LIGAND PHARMACEUTICALS INCORPORATED (US) | 2009-01-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090030027-A1 | Androgen Receptor Modulator Compounds and Methods | AR, NR5A1, ESRRA | AR 1/4885TLR9 3988/4885TLR8 3121/4885 |
| US-20090264455-A9 | Androgen Receptor Modulator Compounds and Methods | AR, NR5A1, ESRRA | AR 1/4885TLR9 3988/4885TLR8 3121/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.